Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells

Cellular and Molecular Life Sciences

Volumn 72, Issue 24, 2015, Pages 4867-4884

  Zeng, Qingyu ^a   Zhang, Hai ^a   Qin, Jiamin ^a   Xu, Zhigang ^a   Gui, Lin ^a   Liu, Beibei ^a   Liu, Chunxiao ^a   Xu, Chong ^a   Liu, Wen ^a   Zhang, Shuangquan ^a   Huang, Shile ^b   Chen, Long ^a  

^a NANJING NORMAL UNIVERSITY   (China)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

B cells; BAFF; Erk1 2; mTOR; PP2A; Rapamycin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; B CELL ACTIVATING FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; RAPAMYCIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TNFSF13B PROTEIN, HUMAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DAUDI CELL LINE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAJI CELL LINE; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84947614179     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-015-1976-1     Document Type: Article

References (62)

1. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-1756
2. Henley T, Kovesdi D, Turner M (2008) B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur J Immunol 38:3543-3548
3. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260-263
4. Mueller CG, Boix C, Kwan WH, Daussy C, Fournier E, Fridman WH et al (2007) Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. J Leukoc Biol 82:567-575
5. Mackay F, Silveira PA, Brink R (2007) B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 19:327-336
6. Schneider P, Tschopp J (2003) BAFF and the regulation of B cell survival. Immunol Lett 88:57-62
7. Fu L, Lin-Lee YC, Pham LV, Tamayo AT, Yoshimura LC, Ford RJ (2009) BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-κB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 113:4627-4636
8. Moisini I, Davidson A (2009) BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 158:155-163
9. Mackay F, Ambrose C (2003) The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 14:311-324
10. Zhang X, Park CS, Yoon SO, Li L, Hsu YM, Ambrose C et al (2005) BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 17:779-788
11. Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A (2006) BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med 203:2551-2562
12. Sanz I, Lee FE (2010) B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6:326-337
13. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D et al (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256-1264
14. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ et al (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10
15. Sasaki Y, Derudder E, Hobeika E, Pelanda R, Reth M, Rajewsky K et al (2006) Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 24:729-739
16. Cornec D, Devauchelle-Pensec V, Tobon GJ, Pers JO, Jousse-Joulin S, Saraux A (2012) B cells in Sjogren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 39:161-167
17. Ramanujam M, Davidson A (2008) BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 223:156-174
18. Otipoby KL, Sasaki Y, Schmidt-Supprian M, Patke A, Gareus R, Pasparakis M et al (2008) BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Natl Acad Sci USA 105:12435-12438
19. Woodland RT, Fox CJ, Schmidt MR, Hammerman PS, Opferman JT, Korsmeyer SJ et al (2008) Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 111:750-760
20. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A (2006) Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 54:2983-2988
21. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274-293
22. Shimobayashi M, Hall MN (2014) Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15:155-162
23. Fernandez D, Perl A (2010) mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov Med 9:173-178
24. Ke Z, Liang D, Zeng Q, Ren Q, Ma H, Gui L et al (2013) hsBAFF promotes proliferation and survival in cultured B lymphocytes via calcium signaling activation of mTOR pathway. Cytokine 62:310-321
25. Junttila MR, Li SP, Westermarck J (2008) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22:954-965
26. Shi Y (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139:468-484
27. Sunahori K, Nagpal K, Hedrich CM, Mizui M, Fitzgerald LM, Tsokos GC (2013) The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients. J Biol Chem 288:21936-21944
28. Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC (2005) Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 115:3193-3204
29. Endong L, Shijie J, Sonobe Y, Di M, Hua L, Kawanokuchi J et al (2011) The gap-junction inhibitor carbenoxolone suppresses the differentiation of Th17 cells through inhibition of IL-23 expression in antigen presenting cells. J Neuroimmunol 240-241:58-64
30. Crispin JC, Apostolidis SA, Rosetti F, Keszei M, Wang N, Terhorst C et al (2012) Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J Immunol 188:3567-3571
31. Crispin JC, Hedrich CM, Tsokos GC (2013) Gene-function studies in systemic lupus erythematosus. Nat Rev Rheumatol 9:476-484
32. Lin MY, Zal T, Ch'en IL, Gascoigne NR, Hedrick SM (2005) A pivotal role for the multifunctional calcium/calmodulin-dependent protein kinase II in T cells: from activation to unresponsiveness. J Immunol 174:5583-5592
33. 2+ homeostasis regulates ERK1/2 activity and cell proliferation in B cells in vitro. Physiol Res 58:411-418
34. 2+-CaMKII-dependent inhibition of PP2A in normal and neoplastic B-lymphoid cells. Biochem Pharmacol 87:332-343
35. Peterson RT, Desai BN, Hardwick JS, Schreiber SL (1999) Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein. Proc Natl Acad Sci USA 96:4438-4442
36. Cao P, Mei JJ, Diao ZY, Zhang S (2005) Expression, refolding, and characterization of human soluble BAFF synthesized in Escherichia coli. Protein Expr Purif 41:199-206
37. Liu L, Chen L, Luo Y, Chen W, Zhou H, Xu B et al (2010) Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS ONE 5:e10578
38. Chen L, Liu L, Yin J, Luo Y, Huang S (2009) Hydrogen peroxide-induced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway. Int J Biochem Cell Biol 41:1284-1295
39. Liu L, Luo Y, Chen L, Shen T, Xu B, Chen W et al (2010) Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem 285:38362-38373
40. Chen L, Liu L, Luo Y, Huang S (2008) MAPK and mTOR pathways are involved in cadmium-induced neuronal apoptosis. J Neurochem 105:251-261
41. Janssens V, Goris J, Van Hoof C (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15:34-41
42. Janssens V, Goris J (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353:417-439
43. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153-166
44. Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F et al (2003) Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 101:278-285
45. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM (2007) Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 83:1114-1121
46. Klein EA, Assoian RK (2008) Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 121:3853-3857
47. Leontieva OV, Demidenko ZN, Blagosklonny MV (2013) MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ 20:1241-1249
48. Moon DO, Park C, Heo MS, Park YM, Choi YH, Kim GY (2007) PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway. Int Immunopharmacol 7:36-45
49. Hardie DG, Haystead TA, Sim AT (1991) Use of okadaic acid to inhibit protein phosphatases in intact cells. Methods Enzymol 201:469-476
50. Erbay E, Chen J (2001) The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. J Biol Chem 276:36079-36082
51. Kaneko T, Amano H, Kawano S, Minowa K, Ando S, Watanabe T et al (2014) Increased serum concentration of BAFF/APRIL and IgA2 subclass in patients with mixed connective tissue disease complicated by interstitial lung disease. Mod Rheumatol 24:310-315
52. Zhou H, Luo Y, Huang S (2010) Updates of mTOR inhibitors. Anticancer Agents Med Chem 10:571-581
53. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP (2006) Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118:281-292
54. Huang X, Di Liberto M, Cunningham AF, Kang L, Cheng S, Ely S et al (2004) Homeostatic cell-cycle control by BLyS: induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci USA 101:17789-17794
55. Tirado OM, Mateo-Lozano S, Notario V (2005) Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 24:3348-3357
56. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L et al (2006) Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66:6589-6597
57. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ (2006) Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169:2171-2180
58. Han X, Xu B, Beevers CS, Odaka Y, Chen L, Liu L et al (2012) Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis 33:868-875
59. Bakema JE, Bakker A, de Haij S, Honing H, Bracke M, Koenderman L et al (2008) Inside-out regulation of Fc alpha RI (CD89) depends on PP2A. J Immunol 181:4080-4088
60. Crispin JC, Apostolidis SA, Finnell MI, Tsokos GC (2011) Induction of PP2A Bbeta, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proc Natl Acad Sci USA 108:12443-12448
61. Roskoski R Jr (2012) ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 66:105-143
62. Shu L, Zhang X, Houghton PJ (2002) Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin. J Biol Chem 277:16726-16732